<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05075499</url>
  </required_header>
  <id_info>
    <org_study_id>8182-21 SMC</org_study_id>
    <nct_id>NCT05075499</nct_id>
  </id_info>
  <brief_title>Immune Response to COVID-19 Vaccine in Multiple Sclerosis Patients Treated With Teriflunomide and Alemtuzumab</brief_title>
  <official_title>LONGEVITY OF IMMUNE RESPONSE TO COVID-19 VACCINE IN VACCINATED MULTIPLE SCLEROSIS PATIENTS TREATED WITH TERIFLUNOMIDE (AUBAGIO) OR ALEMTUZUMAB (LEMTRADA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase IV, 3-armed, prospective, open-label, single-center, Israeli study, examining the&#xD;
      response to SARS-CoV-2 vaccination in 30 teriflunomide-, 10 alemtuzumab-treated patients, and&#xD;
      30 age-matched (for the teriflunomide group) untreated MS patients. Treatments will be&#xD;
      administered according to common local practice. Demographic, clinical, treatment-related and&#xD;
      COVID-19-related data will be collected. Blood samples will be drawn for each participant at&#xD;
      baseline (before COVID-19 vaccination), and at 1, 3, 6, (and possibly 12) months post 2nd&#xD;
      dose of COVID-19 vaccine. Humoral, B-cell and T-cell responses will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of SARS-COV-2 antibody positive MS COVID-19 vaccinees at 1-month post 2nd COVID-19 vaccine dose.</measure>
    <time_frame>6 months</time_frame>
    <description>Detection of SARS-CoV-2 IgG antibodies in blood samples will be performed using Euroimmun (EI, Lubeck, Germany) anti-SARS-CoV-2 IgG quantitative ELISA kit based on a recombinant S1 subunit of the SARS-CoV-2 spike protein</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of SARS-COV-2 antibody positive MS COVID-19 vaccinees at 3 and 6 months post 2nd COVID-19 vaccination.</measure>
    <time_frame>12months</time_frame>
    <description>Detection of SARS-CoV-2 IgG antibodies in blood samples will be performed using Euroimmun (EI, Lubeck, Germany) anti-SARS-CoV-2 IgG quantitative ELISA kit based on a recombinant S1 subunit of the SARS-CoV-2 spike protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SARS-COV-2 antibody titer at 1,3 and 6 months post 2nd COVID-19 vaccination.</measure>
    <time_frame>12 months</time_frame>
    <description>Detection of SARS-CoV-2 IgG antibodies in blood samples will be performed using Euroimmun (EI, Lubeck, Germany) anti-SARS-CoV-2 IgG quantitative ELISA kit based on a recombinant S1 subunit of the SARS-CoV-2 spike protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SARS-COV-2 B-cell memory response at 1,3 and 6 months post 2nd COVID-19 vaccination.</measure>
    <time_frame>12 months</time_frame>
    <description>Reversed antigen human IgG SARS-CoV-2 receptor-binding domain (RBD) ELISpotPLUS will be used according to the manufacturer instructions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of MS COVID-19 vaccinees with SARS-COV-2 T-cell memory positive response at 1,3 and 6 months post 2nd COVID-19 vaccination.</measure>
    <time_frame>12 months</time_frame>
    <description>Positive T cell response will be calculated according to the highest number of IFN-Î³/IL-2 secreting cells in the FluoroSpot</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SARS-COV-2 T-cell memory response at 1,3 and 6 months post 2nd COVID-19 vaccination.</measure>
    <time_frame>12 months</time_frame>
    <description>As indicated in outcome #5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of MS COVID-19 vaccinees with positive double immune response (two responses of the possible three), or positive triple immune response (IgG, T-cell and B-cell memory positive) at 6 months post 2nd COVID-19 vaccination.</measure>
    <time_frame>6 months</time_frame>
    <description>Statistical analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of MS COVID-19 vaccinees with SARS-COV-2 B-cell memory positive response at 1,3 and 6 months post 2nd COVID-19 vaccination. Positive cut-off value will be determined as higher than 10 SFU.</measure>
    <time_frame>6 months</time_frame>
    <description>Statistical analysis</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>MS no immunomodulatory treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MS patients receiving no immunomodulatory treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MS Teriflunomide treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MS patients under treatment with Teriflunomide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MS Alemtuzumab treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MS patients under treatment with Alemtuzumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COVID-19 vaccination</intervention_name>
    <description>Blood sample obtained before, 1 , 3 and 6 months after the intervention</description>
    <arm_group_label>MS Alemtuzumab treatment</arm_group_label>
    <arm_group_label>MS Teriflunomide treatment</arm_group_label>
    <arm_group_label>MS no immunomodulatory treatment</arm_group_label>
    <other_name>Blood withdrawn</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        (1) Diagnosis of multiple sclerosis (MS) according to 2017 McDonald criteria. (2) Age &gt;=18&#xD;
        years.&#xD;
&#xD;
        (3) Treatment with Teriflunomide for at least 6 months/or 4 to 18 months after the last&#xD;
        course treatment with Alemtuzumab/or untreated.&#xD;
&#xD;
        (4) Signed written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        (1) Cognitive decline that precludes understanding the study procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anat Achiron, MD, PhD</last_name>
    <phone>97235303932</phone>
    <email>anat.achiron@sheba.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sue Mayost, LLB</last_name>
    <phone>97235305992</phone>
    <email>Sue.Mayost@sheba.health.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shani Tomer</last_name>
      <phone>97235303932</phone>
      <email>Shani.Tomer@sheba.health.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Maria Didikin</last_name>
      <email>Maria.Didikin@sheba.health.gov.il</email>
    </contact_backup>
    <investigator>
      <last_name>Anat Achiron, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 6, 2021</study_first_submitted>
  <study_first_submitted_qc>October 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Prof. Anat Achiron</investigator_full_name>
    <investigator_title>Director, Multiple Sclerosis Center</investigator_title>
  </responsible_party>
  <keyword>Multiple sclerosis</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Vaccination</keyword>
  <keyword>Teriflunomide (Aubagio)</keyword>
  <keyword>Alemtuzumab (Lemtrada)</keyword>
  <keyword>Immune responses</keyword>
  <keyword>IgG</keyword>
  <keyword>B-cells</keyword>
  <keyword>T-cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>PMID</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://pubmed.ncbi.nlm.nih.gov/32532623/</doc_url>
      <doc_comment>Study scientific background</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>PMID</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://apps.who.int/iris/handle/10665/338671</doc_url>
      <doc_comment>Study scientific background. World Health Organization 2021. Background document on mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19.</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>PMID</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://pubmed.ncbi.nlm.nih.gov/32727835/</doc_url>
      <doc_comment>Study scientific background.</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>PMID</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://pubmed.ncbi.nlm.nih.gov/32769063/</doc_url>
      <doc_comment>Study scientific background.</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>PMID</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://pubmed.ncbi.nlm.nih.gov/25636714/</doc_url>
      <doc_comment>Study scientific background.</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>PMID</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://pubmed.ncbi.nlm.nih.gov/24444048/</doc_url>
      <doc_comment>Alemtuzumab medication</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>PMID</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://pubmed.ncbi.nlm.nih.gov/27766281/</doc_url>
      <doc_comment>Alemtuzumab medication</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>PMID</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://pubmed.ncbi.nlm.nih.gov/31898276/</doc_url>
      <doc_comment>Alemtuzumab medication</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>PMID</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://products.sanofi.us/aubagio/aubagio.html</doc_url>
      <doc_comment>Aubagio (teriflunomide) [prescribing information]. Cambridge (MA): Genzyme Corporation; September 2012.</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>PMID</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://pubmed.ncbi.nlm.nih.gov/31898276/</doc_url>
      <doc_comment>Aubagio (teriflunomide) medication</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>PMID</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://pubmed.ncbi.nlm.nih.gov/29275977/</doc_url>
      <doc_comment>Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

